Publications by authors named "Jacques Hamon"

Claim this Profile
D
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.
Stephane Ferretti, Jacques Hamon, Ruben de Kanter, Clemens Scheufler, Rita Andraos-Rey

Nature· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges for the Discovery of Non-Covalent WRN Helicase Inhibitors.
Alisa Heuser, Wassim Abdul Rahman, Elisabeth Bechter, Jutta Blank, Sylvia Buhr, Jacques Hamon

ChemMedChem· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PAX8 and MECOM are interaction partners driving ovarian cancer.
Melusine Bleu, Fanny Mermet-Meillon, Verena Apfel, Louise Barys, Laura Holzer, Jacques Hamon

Nat Commun· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidimensional de novo design reveals 5-HT2B receptor-selective ligands.
Tiago Rodrigues, Nadine Hauser, Daniel Reker, Michael Reutlinger, Tiffany Wunderlin, Jacques Hamon

Angew Chem Int Ed Engl· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient search of chemical space: navigating from fragments to structurally diverse chemotypes.
Anne Mai Wassermann, Peter S Kutchukian, Eugen Lounkine, Tiffany Luethi, Jacques Hamon

J Med Chem· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of the C3a receptor (C3AR1) as the target of the VGF-derived peptide TLQP-21 in rodent cells.
Sebastien Hannedouche, Valerie Beck, Juliet Leighton-Davies, Martin Beibel, Guglielmo Roma, Jacques Hamon

J Biol Chem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.
Pascal Furet, Vito Guagnano, Robin A Fairhurst, Patricia Imbach-Weese, Ian Bruce, Jacques Hamon

Bioorg Med Chem Lett· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.
Joanne Bowes, Andrew J Brown, Jacques Hamon, Wolfgang Jarolimek, Arun Sridhar

Nat Rev Drug Discov· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large-scale prediction and testing of drug activity on side-effect targets.
Eugen Lounkine, Michael J Keiser, Steven Whitebread, Dmitri Mikhailov, Jacques Hamon

Nature· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro safety pharmacology profiling: what else beyond hERG?
Jacques Hamon, Steven Whitebread, Valerie Techer-Etienne, Helene Le Coq, Kamal Azzaoui

Future Med Chem· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping adverse drug reactions in chemical space.
Josef Scheiber, Jeremy L Jenkins, Sai Chetan K Sukuru, Andreas Bender, Dmitri Mikhailov, Jacques Hamon

J Med Chem· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis.
Josef Scheiber, Bin Chen, Mariusz Milik, Sai Chetan K Sukuru, Andreas Bender, Jacques Hamon

J Chem Inf Model· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
Andreas Bender, Josef Scheiber, Meir Glick, John W Davies, Kamal Azzaoui, Jacques Hamon

ChemMedChem· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling promiscuity based on in vitro safety pharmacology profiling data.
Kamal Azzaoui, Jacques Hamon, Bernard Faller, Steven Whitebread, Edgar Jacoby

ChemMedChem· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clustering and rule-based classifications of chemical structures evaluated in the biological activity space.
Ansgar Schuffenhauer, Nathan Brown, Peter Ertl, Jeremy L Jenkins, Paul Selzer, Jacques Hamon

J Chem Inf Model· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.
Bernard Faller, Jianling Wang, Alfred Zimmerlin, Leslie Bell, Jacques Hamon

Expert Opin Drug Metab Toxicol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects.
Stefan Raduner, Adriana Majewska, Jian-Zhong Chen, Xiang-Qun Xie, Jacques Hamon

J Biol Chem· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
Steven Whitebread, Jacques Hamon, Dejan Bojanic, Laszlo Urban

Drug Discov Today· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.
Anne-Claude Dublanchet, Pierre Ducrot, Charles Andrianjara, Margaret O'Gara, Renaud Morales, Jacques Hamon

Bioorg Med Chem Lett· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis